Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the diagnostic biomarkers market grown over the years?
In recent times, there has been a swift expansion in the diagnostic biomarkers market size. This market is anticipated to progress from $65.25 billion in 2024 to $75.67 billion in 2025, with a compound annual growth rate (CAGR) of 16.0%. The previous growth can be credited to factors such as a heightened occurrence of chronic illnesses, breakthroughs in omics technologies, escalating request for individualized medicine, increasing public cognizance about early disease diagnosis, and a rise in non-invasive diagnostic procedures.
What Is the forecasted market size and growth rate for the diagnostic biomarkers market?
The size of the diagnostic biomarkers market is predicted to witness considerable expansion in the coming years, rising to a staggering $136.57 billion by 2029 at a compound annual growth rate (CAGR) of 15.9%. Factors contributing to the growth in the forecast period are the rising implementation of liquid biopsy methodologies, augmented investment in biomarker research, an increasing focus on precision medicine, and its broadening application in neurodegenerative diseases. Noteworthy trends for the forecast period encompass advancements in artificial intelligence and machine learning, the incorporation of multi-omics approaches, the creation of point-of-care diagnostic instruments, a transition towards digital biomarkers, the escalating usage of wearable health monitoring gadgets, as well as a growing emphasis on the process of biomarker validation and standardization.
Get your diagnostic biomarkers market report here!
https://www.thebusinessresearchcompany.com/report/diagnostic-biomarkers-global-market-report
What are the major factors driving growth in the diagnostic biomarkers market?
The diagnostic biomarkers market’s growth is being fueled by the increasing occurrence of cancer. The surge in cancer cases can be attributed to factors like the aging demographic, lifestyle alterations, environmental exposure, and enhanced diagnostic skills. Diagnostic biomarkers hold a significant position in cancer treatment by allowing early detection, accurate diagnosis, and tailored treatment plans, thereby enhancing patient prognosis. For instance, the American Cancer Society noted that in January 2024, cancer cases escalated to 2,001,140, a significant rise from 1,958,310 in 2023 – a 2.19% growth rate. This rise in cancer prevalence aids in the expansion of the diagnostic biomarkers market.
What key areas define the segmentation of the global diagnostic biomarkers Market?
The diagnostic biomarkers market covered in this report is segmented –
1) By Product: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers
2) By Application: Oncology, Metabolic Disease, Neurological Disease
3) By End User: Hospitals, Cancer Research Institutes, Diagnostic Labs
Subsegments:
1) By Safety Biomarkers: Toxicity Biomarkers, Organ-Specific Safety Biomarkers, Drug-Induced Injury Biomarkers
2) By Efficacy Biomarkers: Predictive Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers
3) By Validation Biomarkers: Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21171&type=smp
What are the top market players propelling the growth of the diagnostic biomarkers industry?
Major companies operating in the diagnostic biomarkers market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, PerkinElmer Inc., Siemens Healthineers AG, Merck KGaA, Agilent Technologies Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen N.V., Myriad Genetics Inc., Meso Scale Diagnostics LLC, EKF Diagnostics Holdings Plc, Sino Biological Inc., Enzo Biochem Inc., Biomarker Technologies Inc., Cisbio Bioassays, Signosis Inc., Epigenomics AG, LifeSign LLC, Banyan Biomarkers Inc., Biosims Technologies SAS
What are the key trends shaping the future of the diagnostic biomarkers market?
Leading organizations within the diagnostic biomarkers sector are focusing their efforts on creating non-invasive test methodologies such as blood-based biomarker evaluations to heighten patient convenience and personalized treatment plans. A blood-based biomarker assessment is a diagnostic device that scrutinizes specific bio-indicators found in the blood to identify and supervise afflictions like Alzheimer’s in the least invasive way possible. For instance, in July 2023, Quanterix Corporation, stationed in the US and specializing in life sciences, unveiled LucentAD, a pioneering blood-based biomarker test developed to support healthcare professionals in diagnosing Alzheimer’s disease in individuals displaying early cognitive symptoms. The test studies the plasma concentration of phosphorylated tau protein at the 181 residue (p-Tau 181), a biomarker connected to amyloid pathology in the brain, a critical sign of Alzheimer’s. LucentAD, by offering a minimally invasive and highly accessible diagnostic tool surpassing traditional alternatives such as cerebrospinal fluid assessment or amyloid positron emission tomography, aspires to simplify the diagnostic process for potential Alzheimer’s patients.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21171
What regions are dominating the diagnostic biomarkers market growth?
North America was the largest region in the diagnostic biomarkers market in 2024. The regions covered in the diagnostic biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Breast Cancer Monoclonal Antibodies Global Market Report 2025
Cancer Biologics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report
Cell and Gene Therapy Global Market Report 2025
https://thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
